GlucoTrack Inc (GCTK) Stock Analysis
Verdict: AVOID
Severe toxic dilution and under 1 month cash runway overwhelm any biopharma asset pipeline potential post-Lokahi merger.
Investment score: 7/100
Analysis as of
Is GlucoTrack Inc stock worth reviewing? The TradeMates thesis
The TradeMates model strongly advises avoiding GCTK due to imminent cash exhaustion, negative stockholders' equity (-$1.74M), and continuous toxic debt dilution.
7-factor investment score
- Valuation: 5/100 (weight 20%)
- Financial Health: 2/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 10/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
GlucoTrack Inc opportunities and risks
What speaks for GCTK
- Biopharma Pipeline Sourcing via Lōkahi ai² Platform
What speaks against GCTK
- Imminent Cash Exhaustion and Runway Under 1 Month
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GCTK | n/a | 0.0x | n/a | 0.0% | 0.0% | -1269.1% |
| BJDX | n/a | 0.0x | 1.3x | 0.0% | 0.0% | -1076.5% |
| RMSL | n/a | 91.4x | n/a | -0.8% | -11339590839.7% | -20646217.5% |
| UAHC | 180.0x | 0.0x | n/a | 0.0% | 0.0% | 40.8% |
| XAIR | n/a | 0.2x | n/a | 4.2% | -435.7% | -1443.1% |
| NXL | n/a | 5.8x | n/a | -148.4% | -4139.4% | -495.1% |
| Peer median | n/a | 0.2x | n/a | 0.0% | -435.7% | -1076.5% |
Frequently asked questions about GlucoTrack Inc (GCTK)
Is GCTK stock a good investment?
The TradeMates model rates GlucoTrack Inc as AVOID with an investment score of 7/100. The TradeMates model strongly advises avoiding GCTK due to imminent cash exhaustion, negative stockholders' equity (-$1.74M), and continuous toxic debt dilution. This is algorithmic model output, not personal investment advice.
Is GCTK stock a buy?
The TradeMates model verdict for GCTK is AVOID with an investment score of 7/100. Treat this as a model signal to review, not a personal buy recommendation.